We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+14.07%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$705M
AUM Growth
+$41.3M
Cap. Flow
+$7.11M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.32%
Holding
99
New
15
Increased
51
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$24.2M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$16.8M
3
CLSD
Clearside Biomedical
CLSD
+$13.9M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$8.94M
5
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$8.79M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$23.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$10.6M
3
CELG
Celgene Corp
CELG
+$10M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$9.47M
5
RMTI icon
Rockwell Medical
RMTI
+$8.3M

Sector Composition

Rank Sector Weight
1 Healthcare 87.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMDZ
51
DELISTED
Immune Design Corp.
IMDZ
$3.53M 0.5%
432,990
+243,990
+129% +$3.04M
OTLK icon
52
Outlook Therapeutics
OTLK
$194M
$3.49M 0.5%
+6,420
New +$3.83M
ZYNE
53
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$3.29M 0.47%
480,501
+5,466
+1% +$45.7K
CRVS icon
54
Corvus Pharmaceuticals
CRVS
$1.11B
$3.05M 0.43%
+214,132
New +$2.89M
CFRX
55
DELISTED
ContraFect Corporation
CFRX
$2.43M 0.34%
1,051
+8
+0.8% +$20.3K
APTO
56
DELISTED
Aptose Biosciences, Inc.
APTO
$2.42M 0.34%
2,201
-203
-8% -$240K
LPCN icon
57
Lipocine
LPCN
$17.4M
$2.28M 0.32%
44,194
+4,978
+13% +$771K
SNDX icon
58
Syndax Pharmaceuticals
SNDX
$1.73B
$2.11M 0.3%
214,419
– –
AGIO icon
59
Agios Pharmaceuticals
AGIO
$1.95B
$2.1M 0.3%
+50,000
New +$2.47M
CBIO
60
Crescent Biopharma
CBIO
$555M
$2.09M 0.3%
2,870
+34
+1% +$23.4K
BPMC
61
DELISTED
Blueprint Medicines
BPMC
$2.05M 0.29%
+101,226
New +$1.84M
CYAD
62
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.9M 0.27%
75,920
+920
+1% +$43.8K
CRIS icon
63
Curis
CRIS
$9.67M
$1.84M 0.26%
588
+7
+1% +$25K
EPZM
64
DELISTED
Epizyme, Inc
EPZM
$1.63M 0.23%
159,513
-106,737
-40% -$1.19M
RGNX icon
65
Regenxbio
RGNX
$648M
$1.25M 0.18%
156,741
– –
AVEO
66
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$1.04M 0.15%
108,772
– –
NGNE icon
67
Neurogene
NGNE
$670M
$1M 0.14%
7,592
+92
+1% +$14.6K
FOLD
68
DELISTED
Amicus Therapeutics
FOLD
$829K 0.12%
151,838
+1,838
+1% +$12.9K
ASND icon
69
Ascendis Pharma A/S
ASND
$16.5B
$826K 0.12%
62,254
+754
+1% +$11.6K
PVCT
70
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$824K 0.12%
2,226,961
+26,961
+1% +$10.3K
GNVC
71
DELISTED
GenVec, Inc.
GNVC
$682K 0.1%
119,065
+1,441
+1% +$10.1K
MTEM
72
DELISTED
Molecular Templates, Inc.
MTEM
$643K 0.09%
6,135
+74
+1% +$5.3K
HTGM
73
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$529K 0.08%
1,130
+13
+1% +$6.6K
NSTG
74
DELISTED
NanoString Technologies, Inc.
NSTG
$510K 0.07%
40,490
+490
+1% +$7.11K
NEOS
75
DELISTED
Neos Therapeutics, Inc
NEOS
$470K 0.07%
50,613
+613
+1% +$5.85K
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Cormorant Asset Management held 99 positions worth $705M, up 6.2% from $664M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Cormorant Asset Management's Q2 2016 filing shows 15 new, 51 increased, 12 reduced and 16 closed positions. Its largest new stake was Theravance Biopharma: 1,118,372 shares worth $25.4M. The largest sale was Alkermes, an estimated $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 86% a quarter earlier.

  • Cormorant Asset Management's largest Q2 2016 buy was Theravance Biopharma: 1,118,372 shares worth $25.4M.
  • Cormorant Asset Management added most to Minerva Neurosciences in Q2 2016, an estimated $8.32M increase.
  • Cormorant Asset Management's biggest Q2 2016 reduction was Neurocrine Biosciences, cutting an estimated $9.47M.
  • Cormorant Asset Management fully exited Alkermes in Q2 2016, selling an estimated $23.9M.
  • Cormorant Asset Management's ten largest holdings make up 40% of its $705M portfolio in Q2 2016.
  • Cormorant Asset Management opened 15 new positions and closed 16 in Q2 2016.
  • Cormorant Asset Management's portfolio value rose 6.2% quarter-over-quarter to $705M.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.